JP1302 is a selective α2C adrenoceptor antagonist with a Kb value of 16 nM and a Ki of 28 nM for human α2C receptors.JP1302 has antidepressant activity, disrupts the FACT complex and degrades histone H1.JP1302 has been used in the study of neuropsychiatric disorders, acute renal failure, and renal injury.

α2C-adrenoceptor (human):28±2 nM (Ki), α2B-adrenoceptor (human):1470±130 nM (Ki), α2D-adrenoceptor (rodent):1700±200 nM (Ki), α2A-adrenoceptor (human):3150±50 nM (Ki)

JP1302 exhibits approximately a 100-fold greater affinity compared to α2A or α2B.[1]

JP1302 (5 μmol/kg; once; Sprague-Dawley rats) is capable of complete reversal of the impairment in PPI induced in Sprague-Dawley rats by the psychotomimetic NMDA receptor antagonist, phencyclidine, and similar results are found in Wistar rats.[1]
JP1302 (1-10 μmol/kg) decreases immobility time in the FST to a level similar to that seen with 10-30 μmol/kg of the antidepressant Desipramine.[1]
JP1302 (3 mg/kg; IV, pre-treatment: administered 5 min before the induction of ischemia, post-treatment: injected 45 min after the initiation of reperfusion; once; Male Sprague Dawley rats ) significantly ameliorated renal dysfunction in the rats at 24 h after reperfusion. post-ischemic administration of JP-1302 significantly ameliorated renal dysfunction, and histological damage and reduced apoptotic cells and pro-inflammatory cytokine mRNA expression.[3]